Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers

Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum–pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous, with outcome...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2026-02-01
Schriftenreihe:	Current Oncology
Schlagworte:	malignant pleural mesothelioma immune checkpoint inhibitors biomarkers tumor microenvironment genomic alterations immunotherapy outcomes
Online-Zugang:	https://www.mdpi.com/1718-7729/33/2/93
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!